Kennedy Capital Management LLC Raises Stock Holdings in Hologic, Inc. $HOLX

by · The Markets Daily

Kennedy Capital Management LLC increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 11.8% in the second quarter, according to its most recent filing with the SEC. The fund owned 85,029 shares of the medical equipment provider’s stock after acquiring an additional 9,007 shares during the period. Kennedy Capital Management LLC’s holdings in Hologic were worth $5,540,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Capital Investment Counsel Inc grew its holdings in shares of Hologic by 2.6% in the second quarter. Capital Investment Counsel Inc now owns 5,814 shares of the medical equipment provider’s stock worth $379,000 after purchasing an additional 150 shares during the last quarter. Greenleaf Trust boosted its position in Hologic by 5.1% in the 2nd quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock valued at $233,000 after buying an additional 173 shares during the period. Schroder Investment Management Group grew its stake in Hologic by 1.4% in the 2nd quarter. Schroder Investment Management Group now owns 15,758 shares of the medical equipment provider’s stock worth $1,027,000 after acquiring an additional 210 shares in the last quarter. Savant Capital LLC increased its position in shares of Hologic by 1.2% during the second quarter. Savant Capital LLC now owns 19,606 shares of the medical equipment provider’s stock worth $1,278,000 after acquiring an additional 232 shares during the period. Finally, First American Bank raised its stake in shares of Hologic by 0.9% during the second quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock valued at $1,870,000 after acquiring an additional 245 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

Shares of HOLX stock opened at $74.97 on Friday. The stock’s 50-day moving average is $72.28 and its 200 day moving average is $67.60. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $80.31. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06. The company has a market cap of $16.71 billion, a P/E ratio of 30.23, a PEG ratio of 2.13 and a beta of 0.70.

Hologic (NASDAQ:HOLX – Get Free Report) last announced its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.03 billion. During the same period in the previous year, the company posted $1.01 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. Research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently issued reports on HOLX. Morgan Stanley increased their price objective on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 11th. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research report on Tuesday, November 4th. Mizuho downgraded Hologic from an “outperform” rating to a “neutral” rating and lifted their price objective for the company from $70.00 to $78.00 in a report on Thursday, October 23rd. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $78.00 price objective on shares of Hologic in a research note on Wednesday, October 22nd. Finally, BTIG Research reissued a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. Five equities research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the stock. According to MarketBeat, Hologic presently has an average rating of “Hold” and a consensus price target of $79.67.

View Our Latest Stock Report on Hologic

Insider Buying and Selling

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total transaction of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. The trade was a 13.52% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 1.88% of the company’s stock.

Hologic Company Profile

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Featured Articles

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Free Report).